|
EP300 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 9.40320044051646E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.45570000001472E-07 |
| Normal-vs-Stage2 |
4.25550000000552E-05 |
| Normal-vs-Stage3 |
6.08500028143055E-10 |
| Normal-vs-Stage4 |
1.17689999967752E-08 |
| Stage1-vs-Stage2 |
5.678800E-01 |
| Stage1-vs-Stage3 |
5.971700E-02 |
| Stage1-vs-Stage4 |
3.718100E-02 |
| Stage2-vs-Stage3 |
4.552000E-01 |
| Stage2-vs-Stage4 |
2.455200E-01 |
| Stage3-vs-Stage4 |
4.850600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
5.0602000367661E-09 |
| Normal-vs-AfricanAmerican |
1.816510E-03 |
| Normal-vs-Asian |
2.773600E-04 |
| Caucasian-vs-AfricanAmerican |
8.082200E-01 |
| Caucasian-vs-Asian |
6.057800E-01 |
| AfricanAmerican-vs-Asian |
9.086200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
7.84349996063582E-09 |
| Normal-vs-Female |
7.57450002719651E-09 |
| Male-vs-Female |
3.834800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.61709999996407E-06 |
| Normal-vs-Age(41-60Yrs) |
7.34579996830576E-09 |
| Normal-vs-Age(61-80Yrs) |
1.44390055467625E-10 |
| Normal-vs-Age(81-100Yrs) |
2.443800E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.393780E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.210140E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.310200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.915440E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.992200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.563800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.112010E-01 |
| Classical-VS-Follicular |
2.624800E-04 |
| Classical-VS-Other |
1.681560E-01 |
| Classical-VS-Normal |
1.15720000004593E-06 |
| Tall-VS-Follicular |
4.442200E-01 |
| Tall-VS-Other |
5.340200E-01 |
| Tall-VS-Normal |
4.37730000002468E-06 |
| Follicular-VS-Other |
8.494800E-01 |
| Follicular-VS-Normal |
7.89379672738733E-11 |
| Other-VS-Normal |
3.235400E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
6.16170003908678E-09 |
| Normal-vs-N1 |
2.30540000001334E-06 |
| N0-vs-N1 |
9.733400E-01 |
|
|
